Antares Pharma to Present at the 11th Annual Needham Healthcare Conference

Needham Healthcare Conference 2012

EWING, N.J.--()--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Robert F. Apple, Executive Vice President, Chief Financial Officer, and President of the Parenteral Products Division, will present at the 11th Annual Needham Healthcare Conference Wednesday, April 4, 2012 at 1:20 pm ET (Eastern Time).

A live webcast of the presentation will be available via the “Investor Relations” page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares’ website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton® hGH. In the gel-based area, the Company's FDA approved product is oxybutynin gel 3% for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for marketing in the U.S. and Canada. Antares’ portfolio includes Elestrin® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.

Contacts

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3020 x133
jhowarth@antarespharma.com
or
Westwicke Partners, LLC
John Woolford, 443-213-0506
john.woolford@westwicke.com

Contacts

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3020 x133
jhowarth@antarespharma.com
or
Westwicke Partners, LLC
John Woolford, 443-213-0506
john.woolford@westwicke.com